Increased expression of APAF-1 in low-risk myelodysplastic syndrome: a possible role in the pathophysiology of myelodysplasia

被引:4
|
作者
Benites, Bruno Deltreggia [1 ]
Traina, Fabiola [1 ]
Santos Duarte, Adriana da Silva [1 ]
Lorand-Metze, Irene Gyongyver H. [1 ]
Costa, Fernando Ferreira [1 ]
Saad, Sara Teresinha [1 ]
机构
[1] Univ Estadual Campinas, Dept Internal Med, Hematol & Hemotherapy Ctr, BR-13083970 Campinas, SP, Brazil
基金
巴西圣保罗研究基金会;
关键词
apoptotic protease-activating factor 1 (APAF-1); myelodysplastic syndrome; apoptosis; DEPENDENT APOPTOSIS; CELLS; PROGENITORS; MELANOMA; CANCER;
D O I
10.1111/j.1600-0609.2010.01429.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: APAF-1 is a central component of the intrinsic pathway of apoptosis, where APAF-1 dysregulation results in the development of diverse human neoplasms. The aim of this study was to characterize the mRNA expression levels of APAF-1 transcripts in low-risk and high-risk MDS and to elucidate whether the expression levels of APAF-1 transcripts are modulated with increased apoptosis in CD34+ MDS cells undergoing erythroid differentiation. Methods: APAF-1 (NM_181861) expression was verified, by quantitative RT-PCR, in bone marrow aspirates from 33 patients with myelodysplastic syndromes (MDS), at the time of diagnosis, and in erythroid differentiation cultures from CD34+ from normal donors and patients with MDS. Results: APAF-1 expression was significantly higher in low-risk, compared to high-risk MDS, according to IPSS (P < 0.0001), FAB (P = 0.0265), and cytogenetic risk (P = 0.0134). Low-risk MDS-derived differentiated erythroid cells demonstrated an increased expression of APAF-1, compared with normal cells, accompanied by an augmented rate of apoptosis. Conclusions: Increased expression of APAF-1 in low-risk disease and its positive correlation with the apoptotic rate observed during the erythroblast differentiation of low-risk MDS cells may indicate that the modulation of APAF-1, at the transcriptional level, participates in the pathophysiology of MDS.
引用
收藏
页码:525 / 530
页数:6
相关论文
共 50 条
  • [21] Iron Support in Erythropoietin Treatment in Myelodysplastic Syndrome Patients Affected by Low-Risk Refractory Anaemia: Real-Life Evidence from an Italian Setting
    Giordano, Giulio
    Cutuli, Marco Alfio
    Lucchesi, Alessandro
    Magnifico, Irene
    Venditti, Noemi
    Vergalito, Franca
    Gasperi, Maurizio
    Di Marco, Roberto
    ACTA HAEMATOLOGICA, 2020, 143 (02) : 155 - 162
  • [22] Reduced ribosomal protein gene dosage and p53 activation in low-risk myelodysplastic syndrome
    McGowan, Kelly A.
    Pang, Wendy W.
    Bhardwaj, Rashmi
    Perez, Marcelina G.
    Pluvinage, John V.
    Glader, Bertil E.
    Malek, Reem
    Mendrysa, Susan M.
    Weissman, Irving L.
    Park, Christopher Y.
    Barsh, Gregory S.
    BLOOD, 2011, 118 (13) : 3622 - 3633
  • [23] Evolution of iron overload in patients with low-risk myelodysplastic syndrome: iron chelation therapy and organ complications
    Remacha, Angel F.
    Arrizabalaga, Beatriz
    Villegas, Ana
    Soledad Duran, Maria
    Hermosin, Lourdes
    de Paz, Raquel
    Garcia, Marta
    Diez Campelo, Maria
    Sanz, Guillermo
    ANNALS OF HEMATOLOGY, 2015, 94 (05) : 779 - 787
  • [24] Evolution of iron overload in patients with low-risk myelodysplastic syndrome: iron chelation therapy and organ complications
    Ángel F. Remacha
    Beatriz Arrizabalaga
    Ana Villegas
    María Soledad Durán
    Lourdes Hermosín
    Raquel de Paz
    Marta Garcia
    Maria Diez Campelo
    Guillermo Sanz
    Annals of Hematology, 2015, 94 : 779 - 787
  • [25] Impact of a new dosing regimen of epoetin alfa on quality of life and anemia in patients with low-risk myelodysplastic syndrome
    M. A. Aloe Spiriti
    R. Latagliata
    P. Niscola
    A. Cortelezzi
    M. Francesconi
    D. Ferrari
    E. Volpe
    M. Clavio
    A. Grossi
    M. Tambone Reyes
    P. Musto
    M. E. Mitra
    A. Azzarà
    D. Pagnini
    G. D’Arena
    A. Spadano
    E. Balleari
    P. Pecorari
    E. Capochiani
    E. De Biasi
    D. Perego
    B. Monarca
    F. Pisani
    G. Scaramella
    M. C. Petti
    Annals of Hematology, 2005, 84 : 167 - 176
  • [26] Impact of a new dosing regimen of epoetin alfa on quality of life and anemia in patients with low-risk myelodysplastic syndrome
    Spiriti, MAA
    Latagliata, R
    Niscola, P
    Cortelezzi, A
    Francesconi, M
    Ferrari, D
    Volpe, E
    Clavio, M
    Grossi, A
    Reyes, MT
    Musto, P
    Mitra, ME
    Azzarà, A
    Pagnini, D
    D'Arena, G
    Spadano, A
    Balleari, E
    Pecorari, P
    Capochiani, E
    De Biasi, E
    Perego, D
    Monarca, B
    Pisani, F
    Scaramella, G
    Petti, MC
    ANNALS OF HEMATOLOGY, 2005, 84 (03) : 167 - 176
  • [27] Bone marrow fibrosis at diagnosis is associated with TP53 overexpression and adverse prognosis in low-risk myelodysplastic syndrome
    Duarte, Fernando B.
    Barbosa, Maritza C.
    Jesus dos Santos, Talyta E.
    Lemes, Romelia P. G.
    Vasconcelos, Joao P.
    de Vasconcelos, Paulo R. L.
    Rocha, Francisco D.
    Zalcberg, Ilana
    Coutinho, Diego F.
    BRITISH JOURNAL OF HAEMATOLOGY, 2018, 181 (04) : 547 - 549
  • [28] Removal of autologous activated CD4-positive T lymphocytes also results in increased colony-forming units in patients with low and intermediate-1 risk myelodysplastic syndromes
    Zhang Zheng
    Xu Feng
    Li Xiao
    Zhang Qianqiao
    He Qi
    Wu Lingyun
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2011, 86 (01) : 47 - 56
  • [29] The Long-Term Efficacy of Erythropoiesis-Stimulating Agents in Patients With Low-Risk or Intermediate-1-Risk Myelodysplastic Syndrome: Multicenter Real-Life Data
    Aslaner, Muzeyyen
    Geduk, Ayfer
    Acar, Ibrahim Halil
    Polat, Merve Gokcen
    Sunu, Cenk
    Bolaman, Ali Zahit
    Hacibekiroglu, Tugba
    Guvenc, Birol
    Ertop, Sehmus
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S358 - S358
  • [30] Long-Term Efficacy of Erythropoiesis-Stimulating Agents in Patients with Low-Risk or Intermediate-1-Risk Myelodysplastic Syndrome: Multicenter Real-Life Data
    Ak, Muzeyyen Aslaner
    Geduk, Ayfer
    Acar, Ibrahim Halil
    Polat, Merve Gokcen
    Sunu, Cenk
    Bolaman, Ali Zahit
    Hacibekiroglu, Tugba
    Guvenc, Birol
    Ertop, Sehmus
    TURKISH JOURNAL OF HEMATOLOGY, 2023, 40 (02) : 92 - 100